Suppr超能文献

生命早期益生菌干预、特应性和哮喘:临床试验的荟萃分析。

Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials.

机构信息

Division of Pediatric Pulmonology, Department of Pediatrics, University of Miami, Miami, FL, USA.

出版信息

Pediatrics. 2013 Sep;132(3):e666-76. doi: 10.1542/peds.2013-0246. Epub 2013 Aug 19.

Abstract

BACKGROUND AND OBJECTIVE

Probiotics may reduce the risk of atopy and asthma in children. However, results from clinical trials have been conflicting, and several of them may have been underpowered. We performed a meta-analysis of randomized, placebo-controlled trials to assess the effects of probiotic supplementation on atopic sensitization and asthma/wheeze prevention in children.

METHODS

Random-effects models were used to calculate pooled risk estimates. Meta-regression was conducted to examine the effect of potential factors on probiotics efficacy.

RESULTS

Probiotics were effective in reducing total immunoglobulin E (IgE) (mean reduction: -7.59 U/mL [95% confidence interval (CI): -14.96 to -0.22]; P = .044). Meta-regression showed that the reduction in IgE was more pronounced with longer follow-up. Probiotics significantly reduced the risk of atopic sensitization when administered prenatally (relative risk: 0.88 [95% CI: 0.78 to 0.99]; P = .035 for positive result on the skin prick test and/or elevated specific IgE to common allergens) and postnatally (relative risk: 0.86 [95% CI: 0.75 to 0.98]; P = .027 for positive result on skin prick test). Administration of Lactobacillus acidophilus, compared with other strains, was associated with an increased risk of atopic sensitization (P = .002). Probiotics did not significantly reduce asthma/wheeze (relative risk: 0.96 [95% CI: 0.85 to 1.07]).

CONCLUSIONS

Prenatal and/or early-life probiotic administration reduces the risk of atopic sensitization and decreases the total IgE level in children but may not reduce the risk of asthma/wheeze. Follow-up duration and strain significantly modified these effects. Future trials for asthma prevention should carefully select probiotic strain and consider longer follow-up.

摘要

背景与目的

益生菌可能降低儿童特应性和哮喘的风险。然而,临床试验的结果相互矛盾,其中一些可能效力不足。我们进行了一项荟萃分析,纳入了随机、安慰剂对照试验,以评估益生菌补充对儿童特应性致敏和预防哮喘/喘息的效果。

方法

采用随机效应模型计算汇总风险估计值。进行了元回归分析,以研究潜在因素对益生菌疗效的影响。

结果

益生菌能有效降低总免疫球蛋白 E(IgE)(平均降低:-7.59 U/mL [95%置信区间(CI):-14.96 至-0.22];P =.044)。元回归分析显示,随着随访时间的延长,IgE 的降低更为显著。益生菌在产前(相对风险:0.88 [95% CI:0.78 至 0.99];P =.035 时皮试和/或常见过敏原特异性 IgE 升高呈阳性)和产后(相对风险:0.86 [95% CI:0.75 至 0.98];P =.027 时皮试呈阳性)给予时,能显著降低特应性致敏的风险。与其他菌株相比,给予嗜酸乳杆菌与特应性致敏风险增加相关(P =.002)。益生菌不能显著降低哮喘/喘息的风险(相对风险:0.96 [95% CI:0.85 至 1.07])。

结论

产前和/或生命早期益生菌的给予能降低儿童特应性致敏的风险,降低 IgE 总水平,但可能不会降低哮喘/喘息的风险。随访时间和菌株显著改变了这些效果。未来预防哮喘的试验应仔细选择益生菌菌株,并考虑更长的随访时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验